Paper Details

  1. Home
  2. Paper Details

Subcutaneous use of treprostinil in pediatric pulmonary hypertension patients: A report of three cases.

Author: KavgacıAkif, KulaSerdar, TerlemezSemiha, TunaoğluFatma Sedef, İncedereFatma

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This article describes three pediatric cases of pulmonary arterial hypertension in whom subcutaneous treprostinil was used.
Paper Details　
Original Abstract of the Article :
Treprostinil was approved by the United States Food and Drug Administration for use in the treatment of pulmonary arterial hypertension in 2002. Intravenous or subcutaneous treprostinil is used in pulmonary arterial hypertension patients in the functional classes of II-IV to alleviate exercise-relat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012979/

データ提供：米国国立医学図書館（NLM）

Subcutaneous Treprostinil: A Treatment Option for Pediatric Pulmonary Hypertension

Pulmonary arterial hypertension (PAH), a serious condition characterized by high blood pressure in the arteries of the lungs, can significantly impact the health and well-being of children. This case report describes the use of subcutaneous treprostinil, a vasodilator, in three pediatric patients with PAH.

Treprostinil: A Promising Treatment Option for Pediatric PAH

The case report highlights the potential of subcutaneous treprostinil as a treatment option for pediatric PAH patients, particularly in those with exercise-related symptoms or who require a reduction in epoprostenol treatment due to side effects.

A Beacon of Hope for Children with PAH

Think of PAH as a formidable desert storm, making it difficult for children to breathe and engage in normal activities. Treprostinil, like a beacon of hope in the midst of the storm, can provide relief from the symptoms of PAH, allowing children to live fuller and more active lives.

Dr. Camel's Conclusion

This case report underscores the potential of subcutaneous treprostinil as a valuable treatment option for pediatric PAH patients, offering a glimmer of hope for children living with this challenging condition. Further research is needed to evaluate the long-term safety and efficacy of this treatment approach in children with PAH.

Date :
  1. Date Completed n.d.
  2. Date Revised 2023-03-18
Further Info :

Pubmed ID

36926146

DOI: Digital Object Identifier

PMC10012979

Related Literature

Article Analysis
・Side Effects of treprostinil
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.